Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025Clinical ChemistryOpen Access

B-327 Measurable Residual Disease Monitoring at Acute Myeloid Leukemia Based on Laboratory Data

View Full Paper
Ask AI
Bookmark
Share

Authors

SASheila Siqueira AndradeJMJulia MariniAVAndressa Vaz

Discussion

Loading...

Member takes

Overview

Retrospective analysis evaluates MRD in acute myeloid leukemia patients using flow cytometry, suggesting its critical role in treatment guidance.

Key Points

  • MRD analysis demonstrates essential predictive value for treatment outcomes in acute myeloid leukemia patients.
  • 56% of the analyzed patients were female, with the highest incidence seen in those aged 50 and above.
  • Multiparametric flow cytometry was the primary technique used for MRD detection across various sample types.
  • LAIP characterization revealed lineage infidelity in 40.4% of cases, underscoring the complexity of AML monitoring.

Cite This Study

Andrade et al. (2025) studied this question.

synapsesocial.com/papers/68e040e9a99c246f578b303chttps://doi.org/10.1093/clinchem/hvaf086.714
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries2025
  2. 2Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.2025
  3. 3A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study2025 · 1 citations
  4. 4Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges2025 · 6 citations
  5. 5The Role of Minimal Residual Disease (MRD) in Predicting Relapse in Acute Leukemia2025